ES2806500T3 - Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas - Google Patents

Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas Download PDF

Info

Publication number
ES2806500T3
ES2806500T3 ES16740686T ES16740686T ES2806500T3 ES 2806500 T3 ES2806500 T3 ES 2806500T3 ES 16740686 T ES16740686 T ES 16740686T ES 16740686 T ES16740686 T ES 16740686T ES 2806500 T3 ES2806500 T3 ES 2806500T3
Authority
ES
Spain
Prior art keywords
seq
antibody
binding
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16740686T
Other languages
English (en)
Spanish (es)
Inventor
Beatrice Tien-Yi Wang
Max Allen Schwarzer
Bruce Alan Keyt
Ramesh Baliga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Application granted granted Critical
Publication of ES2806500T3 publication Critical patent/ES2806500T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16740686T 2015-01-20 2016-01-20 Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas Active ES2806500T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105323P 2015-01-20 2015-01-20
PCT/US2016/014153 WO2016118641A1 (en) 2015-01-20 2016-01-20 Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
ES2806500T3 true ES2806500T3 (es) 2021-02-17

Family

ID=56417700

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16740686T Active ES2806500T3 (es) 2015-01-20 2016-01-20 Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas

Country Status (17)

Country Link
US (4) US10689449B2 (cg-RX-API-DMAC7.html)
EP (2) EP3247728B1 (cg-RX-API-DMAC7.html)
JP (4) JP7179464B2 (cg-RX-API-DMAC7.html)
KR (1) KR102435324B1 (cg-RX-API-DMAC7.html)
CN (1) CN107207601A (cg-RX-API-DMAC7.html)
AU (2) AU2016209324B2 (cg-RX-API-DMAC7.html)
CA (1) CA2972990A1 (cg-RX-API-DMAC7.html)
DK (1) DK3247728T3 (cg-RX-API-DMAC7.html)
ES (1) ES2806500T3 (cg-RX-API-DMAC7.html)
HU (1) HUE051013T2 (cg-RX-API-DMAC7.html)
IL (3) IL284430B2 (cg-RX-API-DMAC7.html)
NZ (1) NZ732922A (cg-RX-API-DMAC7.html)
PL (1) PL3247728T3 (cg-RX-API-DMAC7.html)
PT (1) PT3247728T (cg-RX-API-DMAC7.html)
SG (2) SG10202001779UA (cg-RX-API-DMAC7.html)
SI (1) SI3247728T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016118641A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105722855B (zh) 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
CA2939191C (en) 2014-02-10 2023-04-04 Igm Biosciences, Inc. Iga multi-specific binding molecules
CN106459213B (zh) 2014-04-03 2020-12-01 Igm生物科学股份有限公司 修饰的j链
IL284430B2 (en) 2015-01-20 2024-04-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
KR20220018081A (ko) 2015-03-04 2022-02-14 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
JP6882184B2 (ja) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
US10570191B2 (en) 2015-04-17 2020-02-25 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
WO2017059380A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
JP7058213B2 (ja) 2015-09-30 2022-04-21 アイジーエム バイオサイエンシズ インコーポレイテッド 改変ｊ鎖を有する結合分子
AU2017264683B2 (en) 2016-05-09 2024-02-29 Igm Biosciences, Inc. Anti-PD-L1 antibodies
WO2018017889A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
EP3497126A4 (en) * 2016-08-12 2020-04-08 Janssen Biotech, Inc. ANTIBODIES OF FC MODIFIED ANTI-TNFR SUPERFAMILY HAVING IMPROVED AGONIST ACTIVITY AND METHODS OF USE THEREOF
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3606949A1 (en) * 2017-04-06 2020-02-12 Universität Stuttgart Tumor necrosis factor receptor (tnfr) binding protein complex with improved binding and bioactivity
CN110536900B (zh) 2017-04-07 2024-06-11 Igm生物科学股份有限公司 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
CN108251443A (zh) * 2018-01-23 2018-07-06 深圳市人民医院 一种tnfrsf10c重组质粒、制备方法及其应用
WO2019157772A1 (zh) * 2018-02-13 2019-08-22 和元生物技术（上海）股份有限公司 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
US20200392239A1 (en) * 2018-02-26 2020-12-17 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
SG11202008343YA (en) 2018-03-01 2020-09-29 Igm Biosciences Inc IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
KR20210083260A (ko) * 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
EP4582442A3 (en) 2019-06-24 2025-10-29 Universität Stuttgart Tnfr2 agonists with improved stability
JP7378509B2 (ja) * 2019-08-02 2023-11-13 チャンスー シムサー ファーマシューティカル カンパニー リミテッド 抗ｔｎｆｒ２抗体およびその使用
WO2021030688A1 (en) 2019-08-15 2021-02-18 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
WO2021202863A1 (en) * 2020-04-02 2021-10-07 Promab Biotechnologies, Inc. Human ror-1 antibody and anti-ror-1-car-t cells
EP4139362A2 (en) 2020-04-22 2023-03-01 IGM Biosciences Inc. Pd-1 agonist multimeric binding molecules
MX2022014259A (es) * 2020-05-12 2022-12-07 Igm Biosciences Inc Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer.
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
JP7203870B2 (ja) 2021-01-18 2023-01-13 イビデン株式会社 組電池用熱伝達抑制シート及び組電池
EP4314046A4 (en) * 2021-04-01 2025-03-19 ModernaTX, Inc. Mucosal expression of antibody structures and isotypes by mRNA
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
ATE314479T1 (de) 1992-05-18 2006-01-15 Genentech Inc Aktivierung von rezeptoren fähig zur oligomerisierung durch verwendung von fusionierten rezeptor liganden
EP0614984B2 (en) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
CA2139385C (en) 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
PT809510E (pt) 1995-01-26 2004-09-30 Biogen Inc Complexos de linfotoxina-alfa/beta e anticorpos receptores de anti-linfotoxina-beta como agentes anti-tumor
IL116784A (en) 1996-01-16 2000-01-31 Hadasit Med Res Service Device for examining viscoelasticity of a living or artificial tissue
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20060269558A1 (en) 1998-04-27 2006-11-30 Murphy Gerald P Nr-CAM gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
DE60043626D1 (de) 1999-01-07 2010-02-11 Zymogenetics Inc Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
EP1159286A4 (en) 1999-03-04 2003-01-15 Human Genome Sciences Inc TUMOR NECROSIS FACTOR RECEPTORS 6 ALPHA AND 6 BETA
WO2000053223A1 (en) 1999-03-11 2000-09-14 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US7262005B1 (en) 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
AU2001272978A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel co-stimulatory molecules
CA2414272A1 (en) 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US6955717B2 (en) 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
EP1396500A4 (en) * 2001-05-18 2005-02-02 Kirin Brewery ANTI-TRAIL-R ANTIBODIES
EP1401999A4 (en) 2001-05-25 2005-09-14 Amgen Inc PROTEIN-2 MOLECULES ASSOCIATED WITH B7 AND USE THEREOF
US20050214210A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
CA2450129A1 (en) 2001-06-14 2002-12-27 Donald G. Jackson Novel human histone deacetylases
KR20040070254A (ko) 2001-12-20 2004-08-06 휴먼 게놈 사이언시즈, 인코포레이티드 Ｔｒａｉｌ 수용체에 면역특이적으로 결합하는 항체
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
GB0220205D0 (en) 2002-08-30 2002-10-09 Chiron Spa Neisseria toxin
EP1576179B1 (en) 2002-11-27 2010-09-15 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
EP1583773A1 (fr) 2003-01-07 2005-10-12 Biomerieux Polypeptides f' du virus de l'hepatite c, epitopes et leurs applications diagnostiques et therapeutiques
JP5452835B2 (ja) 2003-07-15 2014-03-26 中外製薬株式会社 形質転換細胞によるＩｇＭの産生とその定量方法
DE602004009199T2 (de) 2003-08-01 2008-06-19 Enhan Technology Holdings International Co., Ltd. Wirkungen von sporoderm-gebrochenen germinationsaktivierten ganoderma-sporen auf die behandlung von rückenmarksverletzungen und die proliferation und/oder differenzierung von neuralen stammzellen in verletztem rückenmark
CN100427505C (zh) 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
US8377435B2 (en) 2004-11-05 2013-02-19 The Board Of Trustees Of The Leland Stanford Junior University Antibody induced cell membrane wounding
WO2006063067A2 (en) 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
EP1848732B1 (en) 2005-01-21 2016-07-27 Epitopix, LLC Yersinia spp. polypeptides and methods of use
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060269556A1 (en) 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
US20060269569A1 (en) 2005-05-16 2006-11-30 Liu Yuen Universal antioncotic and pain relieving ointment
US20060269567A1 (en) 2005-05-16 2006-11-30 Liu Yuen Universal detoxifying composition
AU2006249992B2 (en) 2005-05-24 2010-09-02 The United States Of America As Represented By The Secretary Of The Navy Anti-adhesin based passive immunoprophylactic
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
BRPI0706530A2 (pt) 2006-01-13 2011-03-29 Irm Llc métodos e composições para tratamento de doenças alérgicas
CN101074261A (zh) 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
AU2007252295B2 (en) 2006-05-19 2013-07-25 Central Adelaide Local Health Network Incorporated Selective modulation of receptor signalling
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
KR100847010B1 (ko) 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
MY161894A (en) 2006-09-08 2017-05-15 Abbvie Bahamas Ltd Interleukin-13 binding proteins
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
KR20090105913A (ko) 2006-11-02 2009-10-07 다니엘 제이 카폰 이동 부분을 갖는 하이브리드 면역글로불린
WO2009030285A1 (en) 2007-09-07 2009-03-12 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US7960145B2 (en) 2007-11-08 2011-06-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
EP2322220B1 (en) 2008-08-01 2014-01-01 Axis, Inc. Therapeutic agent or preventive agent for osteoarthritis
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
MX341796B (es) 2009-12-29 2016-09-02 Emergent Product Dev Seattle Proteinas de union heterodimericas y usos de las mismas.
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
JP5918143B2 (ja) 2010-10-29 2016-05-18 第一三共株式会社 新規抗ｄｒ５抗体
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
ME03071B (me) 2011-04-21 2019-01-20 Bristol Myers Squibb Co Polipeptidi antitela koji antagonizuju cd40
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US8952134B2 (en) 2011-09-26 2015-02-10 Jn Biosciences Llc Hybrid constant regions
US9382319B2 (en) * 2011-09-26 2016-07-05 Jn Biosciences Llc Hybrid constant regions
HK1200321A1 (en) 2011-10-24 2015-08-07 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17
KR102102111B1 (ko) 2012-02-08 2020-04-20 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄｉｍ 결합 단백질 및 이의 용도
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
DK2879719T3 (en) * 2012-08-01 2018-09-03 Nationwide Childrens Hospital INTRATEKAL ADMINISTRATION OF RECOMBINANT ADENOASSOCATED VIRUSES
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
US9725517B2 (en) 2012-10-26 2017-08-08 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Humanized monoclonal antibodies against the extracellular domain of human death receptor 5
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2994487B1 (en) 2013-05-07 2019-10-09 F.Hoffmann-La Roche Ag Trimeric antigen binding molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
CN105722855B (zh) 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
NZ720353A (en) 2013-12-30 2019-12-20 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
WO2015107126A1 (en) 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
CA2939191C (en) 2014-02-10 2023-04-04 Igm Biosciences, Inc. Iga multi-specific binding molecules
AU2015237864B2 (en) 2014-03-24 2020-12-03 Cancer Research Technology Limited Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
CN106459213B (zh) 2014-04-03 2020-12-01 Igm生物科学股份有限公司 修饰的j链
RU2017116020A (ru) 2014-10-08 2018-11-12 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия биспецифичными антителами, специфичными к fap и dr5, и химиотерапевтические агенты
IL284430B2 (en) 2015-01-20 2024-04-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
RU2017129236A (ru) 2015-01-26 2019-03-07 Макродженикс, Инк. Мультивалентные молекулы, содержащие dr5-связывающие домены
KR20220018081A (ko) 2015-03-04 2022-02-14 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
JP6882184B2 (ja) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
US10570191B2 (en) 2015-04-17 2020-02-25 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
CA2990885A1 (en) 2015-06-30 2017-01-05 Sanford-Burnham Medical Research Institute Btla fusion protein agonists and uses thereof
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
JP7058213B2 (ja) 2015-09-30 2022-04-21 アイジーエム バイオサイエンシズ インコーポレイテッド 改変ｊ鎖を有する結合分子
WO2017059380A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
AU2017264683B2 (en) 2016-05-09 2024-02-29 Igm Biosciences, Inc. Anti-PD-L1 antibodies
WO2018017889A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
AU2017299610B2 (en) 2016-07-20 2022-09-29 Igm Biosciences, Inc. Multimeric CD40 binding molecules and uses thereof
WO2018017761A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
CA3030647A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
UA127449C2 (uk) 2016-09-23 2023-08-30 Мерус Н.В. Зв'язувальна молекула, яка модулює біологічну активність, що експресується клітиною
CN110536900B (zh) 2017-04-07 2024-06-11 Igm生物科学股份有限公司 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区
US20200392239A1 (en) 2018-02-26 2020-12-17 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
SG11202008343YA (en) 2018-03-01 2020-09-29 Igm Biosciences Inc IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
KR20210083260A (ko) 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
WO2021030688A1 (en) 2019-08-15 2021-02-18 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
MX2022002024A (es) 2019-08-17 2022-03-11 Igm Biosciences Inc Moleculas de union anti-cd123 multimericas biespecificas y usos de estas.
CA3149350A1 (en) 2019-08-23 2021-03-04 Igm Biosciences, Inc. Igm glycovariants
CA3151237A1 (en) 2019-09-19 2021-03-25 Ramesh Baliga Multimeric antibodies with enhanced selectivity for cells with high target density
IL293739A (en) 2020-01-06 2022-08-01 Igm Biosciences Inc Highly sialylated multimeric binding molecules
EP4139362A2 (en) 2020-04-22 2023-03-01 IGM Biosciences Inc. Pd-1 agonist multimeric binding molecules
MX2022014259A (es) 2020-05-12 2022-12-07 Igm Biosciences Inc Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer.
WO2022026475A2 (en) 2020-07-27 2022-02-03 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
WO2022109023A1 (en) 2020-11-17 2022-05-27 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
JP2024508709A (ja) 2021-02-17 2024-02-28 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｃｄ１２３結合分子及びその使用法
US20220267415A1 (en) 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof

Also Published As

Publication number Publication date
NZ732922A (en) 2022-07-29
JP2018503401A (ja) 2018-02-08
KR102435324B1 (ko) 2022-08-23
AU2016209324B2 (en) 2020-02-27
IL253054A0 (en) 2017-08-31
JP2024113039A (ja) 2024-08-21
IL308212A (en) 2024-01-01
NZ758252A (en) 2024-11-29
EP3247728A1 (en) 2017-11-29
CA2972990A1 (en) 2016-07-28
CN107207601A (zh) 2017-09-26
IL253054B (en) 2021-08-31
HUE051013T2 (hu) 2021-01-28
US20170320955A1 (en) 2017-11-09
EP3750918A1 (en) 2020-12-16
PT3247728T (pt) 2020-07-16
US20230203173A1 (en) 2023-06-29
EP3247728A4 (en) 2018-07-04
AU2020201323A1 (en) 2020-03-12
SG10202001779UA (en) 2020-04-29
PL3247728T3 (pl) 2020-11-16
JP7499813B2 (ja) 2024-06-14
IL284430A (en) 2021-07-29
US10689449B2 (en) 2020-06-23
JP2021006044A (ja) 2021-01-21
DK3247728T3 (da) 2020-07-13
IL284430B1 (en) 2023-12-01
IL284430B2 (en) 2024-04-01
US9938347B2 (en) 2018-04-10
AU2016209324A1 (en) 2017-07-06
SI3247728T1 (sl) 2020-09-30
JP2022177090A (ja) 2022-11-30
JP7179464B2 (ja) 2022-11-29
US11578131B2 (en) 2023-02-14
AU2020201323B2 (en) 2022-03-31
WO2016118641A1 (en) 2016-07-28
US20180009897A1 (en) 2018-01-11
SG11201705116SA (en) 2017-08-30
EP3247728B1 (en) 2020-04-15
US20210047419A1 (en) 2021-02-18
KR20170105077A (ko) 2017-09-18

Similar Documents

Publication Publication Date Title
ES2806500T3 (es) Moléculas de unión al receptor de la superfamilia de TNF (factor de necrosis tumoral) y usos de las mismas
ES2874558T3 (es) Moléculas de unión a CD20 y usos de las mismas
US20210388098A1 (en) Multimeric cd137/4-1bb binding molecules and uses thereof
ES2914177T3 (es) Anticuerpos anti-OX40 humanizados y usos de los mismos
US20220106399A1 (en) Multimeric cd40 binding molecules and uses thereof
US20190330374A1 (en) Multimeric ox40 binding molecules and uses thereof
WO2018017889A1 (en) Multimeric gitr binding molecules and uses thereof
HK40043005A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348B (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
HK1242348A1 (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof